12:00 AM
 | 
Jan 12, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

ProAmatine midodrine hydrocholride regulatory update

A consortium of generic manufacturers sent letters to FDA suggesting that they would consider conducting the necessary post-marketing studies for midodrine if the agency were to grant assurances that they would be eligible to receive 3-year...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >